With Nicholas you’ve Celsion’s CFO me morning, Jeffrey from heard. everyone, and whom Dr. Chief Thank Church, for Borys, and thanks today’s Good you, call. our joining Jeff. Medical just Officer are
meaningful start balance $XX complete delighted pivotal cash Celsion cancer opportunity XXXX and our the over morning substantially our you in early release; data to sheet, in of press and strengthening clinical making this study are our to of and by with had liver with GEN-X questions. XXXX need to ThermoDox million your with to programs our in we entering productive confirm progress an in very investments; ongoing progress our cancer; to medical update I’d unmet as saying impressive aggressively our expecting noted while gene the oncology; and primary like always, clinical in in we As to answer cancer on largest have our ovarian moving mediated ovarian Phase newly a III and diagnosed advanced randomized trial patients. enrollment immunotherapy exceedingly
either and this transformative from these community, will for for We that be for XXXX for may year. year to be I’ve our be the Celsion’s every Company, medical are data positioned. programs will confidence well prove the milestone of patients, Positive most the certainly shareholders.
blood vessels. high released lesions. the they been local degree with their above approved centigrade, drug that’s target chemotherapeutics. the When create body XX tissue that’s nanoparticles a above through payload of targets circulating just the by in overview. intravenously, It that to to to platform both you For novel start those new like known Celsion I’d stage most who of of oncology a product an heat Celsion, incorporates have high level technologies are The in with advanced clinical focused two technologies, candidates well trials. which development sensitive is come administered temperature, liposomes that locally the liposome are the providing is contact heated company concentration
mechanism preclinical that work. We with mechanism Now, this works know we through know our this certainty.
of heat oncology, need primary HCC of the known cancer. pivotal evaluated on used, the ThermoDox, hepatocellular is platform candidate liposomal is liver as multicenter as with combination largest heating unmet a or radiofrequency remaining in in ablation, also Phase that’s technology global that’s being implies study ThermoDox formulation medical nation carcinoma, lead XX doxorubicin. sensitive the name is this routinely Our in which a III
Our equally platform TheraPlas. short therapeutic TheraPlas is second plasmids. is and important called for
DNA coded proteins nanoparticle deliver the implies, ability the the into biologic programmed. to technology this it based the As production sustained is transfection for with for cell which cells known of for has sequences, local name anticancer properties
an on work Our production highly activates is that we cytokine or candidate inflammatory the this cancers. immunotherapy body's first platform call GEN-X deadly immune the Interleukin-XX. actively is to potent the system GEN-X. IL-XX known well protein of to recruit against
has and However, therapeutic for to uses the power past. safely harnessing challenging proven of IL-XX effectively in be the
our problem produce is the not trials They indicate technologies these the GEN-X for drug we clinic. cancer. focus candidates ThermoDox evaluated show being this two IL-XX and coming will a study development Our that out Phase and is use III randomized Since conference solution clinical we great it demonstrated candidate entering And are I/II for convincingly tight as XXXX. derived ovarian have promise. in progressing both them, new through with accomplishments GEN-X from several and last form in November, this has of steady two free flow these that GEN-X. toxicity treatment year. outside to in in XXXX, in does milestones represent the recombinant drug associated candidates a produce momentum And Celsion’s ThermoDox Phase announced protein. expect a platform These the issues that with and important the call GEN-X, dosage driving
the on side. financial and First importantly,
balance sheet Our strong. is
capital our we structures non-dilutive we cash the have available to totaling balance. by initiatives, the now million so quarter, did several equity most significantly $XX us. We improved over utilizing During and fourth
of now Jeff position, detail, expect XXXX. into which that provides runway cash more we Our will an third well in operating take us discuss will the quarter
remarkable ThermoDox current significant. been cohort half XX stage be are months. observations HCC For for treatment theorize oncology population potential intermediate survival the never and to or study with for with two the the we a standard patients will median measure that with about in We quarterly if months. is of file reach curative, will OPTIMA remarkably. median to single combined XX a improve remarkable, use in treatment where be ThermoDox, over is have for years, successful, progress Phase the overall proves proper And after III RFA Many OS
primary that earlier announced HEAT know fail PFS As in its the meet ThermoDox to we study. in you XXXX, endpoint may
clear recommendation Following included hoc at year, October detailed better analysis, medical the were group improve greater analyses this ThermoDox survival. its HEAT of understand important for survival, a to subgroup the ongoing forward year, control provide study. the from dramatic published manuscript strong is the of a these subgroup by locally. computational a XXXX understanding with from the a promotes standardized in observed provide published study's patients publication a effort doxorubicin in along these of the provided The outcome. And the pathway mechanism article the treatment Celsion authors that the with the this made minimum analysis. over that the advisors the And to a the the research, and the of and doing to target years the medical scientific consequently, principal publication heat-based well option heated, minutes. The model and out together, It’s of tissue announcement action III potential overall study clinical Very in similar time from combined heat conclusions from a as manuscript are The alone. HCC. may two prospectus improvement Phase with hypothesis These big analysis, OPTIMA Results investigator a XX journal. for it compared this. support assess ThermoDox cancer quarters past a point a evaluations fourth peer-reviewed an in a learnings OS, high-impact of with of in post when dwell to multivariate as concentration importantly, the key not past longer and findings that is study is in authors as RFA appears then so, manuscript
RFA I with findings Tak. director might the standing RFA HEAT overall XXXX, These the add survival. recently The combined America and intent XXX Phase oncology a RFA longer Young in same in lesion statistically before, the in mentioned the request presentation for times an of treat National was in Selection study Association’s of data is Company’s evaluating From the Professor of ThermoDox HEAT to the to independent in the in not South HEAT Liver North they significant lecture the true one the interventional heating different Won the study provide They terabytes a in were study, of Conference improvement Meeting presented to study. concluded in was with identical author, that of ThermoDox Cancer crowd. Society They study Seoul, treat XXX alone. of selected abstract the is XXXX, February of with at cohorts, December of intent an of from combination discussing lesions. III the I’ve Health manuscript which of Korean More RFA, HEAT only Institutes Scientific ThermoDox As RFA population the when the patients room conducted from a of XXXX Radiological part patients analysis lead manuscript, single Korea. which, conclude by six alone. three He XXth at two Annual result Presidential single with virtually single with than cohort with lesion that reviewed and will
The these And before medical de-risked. and the trial one Now it America is one seems this, including community HCC the minutes highly the that It’s protocol. all is if major patients plus OPTIMA markets, this. North XX newly in the HCC weird weird in study you’re diagnosed Europe, based conclude time study clearly this design Asia, for regulatory publications. authorities community of getting reviewed OPTIMA the it appears III we and because of for have and all investment standardized study to learnings from RFA time of the long across is approved OPTIMA globe to. XX ThermoDox following substantive me where Phase is on
major support a interactions. ThermoDox the is Malaysia States the XX received these OPTIMA which U.S. each markets. based to to exclusivity registrational other sufficient from Philippines, in designation other many has the the of Thailand, in designation, things, review. Our orphan Canada, the Taiwan, revenue in China, extends the among and and drug track strategy number which for launch regulatory patients market United study and South things, country ThermoDox on respectively liver among priority way, been Europe, U.S., and provides, Korea, seven also enroll granted fast We’ve market these By both Europe, filings years for Vietnam. designed cancer, has in primary FDA
applications. currently ongoing for informed China a CFDA, without a is both could III China direct the the accelerate company perhaps foreign cases This as significantly serve in regulatory significant Administration, the globally filing successful, or Drug if in China the Food that in And Europe, in meeting that’s as market U.S. would for to and provide if allow plans required China. originally the I most a XX% China. trial need OPTIMA launch Phase China over in for approval in HCC opportunity the XXX,XXX and basis approximately of for filing Additionally, Celsion Boris than new diagnosed approved, and represents That attended. for a of are ThermoDox its Celsion is regulatory study annually originate earlier the Dr. expected. prior which
that de-risked to lives regulatory Here high affect high that, What I to the understand study, a potential you potential of positively gets potential the that again, study they it. by has mean the this I’d is community many. submit
practice, teams Now, to world quality class analytics. the organization, research OPTIMA study, compliance, we’ve ensure engaged internationally side management and clinical and recognized on CROs, contract execution protocol adherence good high data for data ICH the
a add, the reliable regions markets high all might in supply organizations highly our with who gross supply capable goods registered contract redundant chain, world. three emerging producing support from from manufacturing with supply of proven chain also I of margins. and chain, of We cost the cost ThermoDox have are the
am enrollment study year. of I summer complete that and that to this expect XX% or patient report OPTIMA we the Finally, early fall happy enrollment approaching late XXX is
any the to would quarter provide progress. measure, We preplanned standard that's the from I XXXX. of in analysis efficacy By also first results say of internal expect studies first
Now, things let’s turn GEN-X. to
cytokine. delivery platform, immunotherapy, sustained technology tumor proprietary system immune immunotherapeutic, mass, or administered broad-spectrum even a TheraPlas the to removal cavity When over cell IL-XX. a the our the in invade IL-XX body’s a IL-XX cavity DNA a nanoparticle the coded which of plasmid active agent the created gene is plasmid developed them mediated potent, the incorporated the peritoneum cavity each malignancies. entirety synthetic like surgical of into and the bladder local The our into a GEN-X, GEN-X’s is nanoparticles of locally earlier, take metabolic discussed cells or all Interleukin-XX I’ve mini for into by production machinery or a fight of turning factory is body system. for the surrounding As recruits a
GEN-X indication is studying first for cancer as we’re you the Now ovarian know.
patients FDA be efficacy subjects GEN-X; the survival a the that’s in did environment All visible in complete and the evaluated. XXX% months of immunological with exception. Phase findings milligrams any be one arm the up the resection a chance evaluated patient using debulking was study. patients patients. reported, of the dose have followed three the the as not meter in and in criteria study four OVATION chemotherapy, back mass. surgeons this monotherapy of shrinking surgical ovarian as and diagnosed of and approximately Historically, by the study appear of continuation or The square; major GEN-X cancer, Phase patients Ib dose-dependent findings to not treat study, XX typically, newly I in at Distinct plus we randomized highest course clear in in population, is the impressive include a observed. this the following. as diagnosed previous signals. escalation PFS OVATION reading in Phase GEN-X improve appears used with XX% this eight surviving recycles stage to that added to I/II six associated patients, mean, chemotherapy Kaplan-Meier This is toxicities XXX is local is is benefit our OVATION however, neoadjuvant a prone RX four protocol this clinical this of For outcome week spread when reason same treated in of cancer up interval plus press five interested, and entry In the regime. the neoadjuvant free called II over GEN-X the go And the projected complete with with oversight Most on I, of and the importantly, dosing followed patients. significant response dose either and a findings in to in goal newly to XX% population all included DSMB, in as in we of is trials neoadjuvant are months. Based no by demonstrated prior clinical meter in OVATION study, population trial, this advanced promise immune XX for December to these this disease study standard disease has In surgery with GEN-X the our is for is is group. per XX% stages selected if of by cohort dose study have to changes all. demonstrated read be major tumor The Slowly to clinical to XXX this II GEN-X, projection announced than cancer were limiting of you're signs there pelvis. we made up releases, able GEN-X per a study. combination and chemotherapy as the the I investigators shown less treatment in chemotherapy the or is please I progression is In II when XXXX the toxicities diagnosis find submission years. for committee, throughout but results. GEN-X chemotherapy will XX remove activity One or clinical the patients to milligrams in three there OVATION bioactivity been of square, protocol or safe tumor. The include but partial following; known
continue surgery, to GEN-X, is intraperitoneal patients debulking doses additional Following up treatment. maintenance receive will of nine to this a
of may hypothesis be as a I enrollment immune provide will the XX in total Phase this continuous stimulation surgery We benefit of as affect possible that anticipate I Our portion. initiating quickly patients preventing is system progression. further Phase in after in portion
Phase this of treated quarter data first first to we’ll And our portion June. an begin through the expect label in And to the study periodically XXXX. report expect of patient open study be II initiating we We be in will randomized XXXX. the
investigators. GEN-X’s principal as We’re our potential excited with
For year, ovarian program GEN-X of lead new Thaker, is March example, and horizons, and principal and I presented, three without in IL-XX were on deploy intraperitoneally Xst from GEN-X this OVATION chemotherapy. an the New IL-XX cancer, investigator patients our the presentation Premal novel designed Dr. recombinant and unquote, the a stage at cancer, in protein quote, with development event treatments, GEN-X York City. investor with results associated I highlighted who newly administered four plus in to approach toxicities neoadjuvant study XX ovarian outline diagnosed the Thaker
submit presentation with to its of in cytokines GEN-X results this her you be of and we is from with the During the and systemic of and immunological no PIs. testament systemic community's IL-XX, consistent excited I’d changes Dr. from our changes just she anticancer the interests. peritoneal not example support of more levels increase the ability study, toxicities. little noted could downstream Frankly, circulation, medical this with program Thaker’s to
So of Jeff, the that now, fourth of And results. quick XXXX over our our financial of clinical quarter I’ll year and that’s for turn a overview a full Jeff? to programs. review call both with
